Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
CUTANEOUS MALIGNANCY UPDATE: MELANOMA IN 2007
Houben R., Ortmann S., Schrama D., Bröcker E.-B., Becker J. C.
Department of Dermatology, Venereology and Allergology Julius-Maximilians University, Würzburg, Germany
The increasing understanding of the molecular pathology of malignancies will have impact on future therapeutic approaches. Effective, non-toxic intervention in a broad range of cancers including melanoma may potentially be provided by targeted therapeutics which are tailored towards the molecular abnormalities that cause tumour progression. a) Constitutive activation of the Ras/MAPK- and PI3K/Akt-signal transduction pathways, b) epigenetic deregulation of gene expression due to drastic changes in DNA methylation and histone modification and c) loss of stability of tumour suppressor proteins have been demonstrated to be involved in melanomagenesis. Small molecular weight inhibitors interfering with these deregulated events, as well as the results of first clinical trials applying these substances are covered in this review.